Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2016-07-12 Capital/Financing Update
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Mauna Kea Technologies annonce une augmentation de capital d’environ 4,4 millions d'euros
Capital/Financing Update Classification · 99% confidence The document is a press release from Mauna Kea Technologies announcing a capital increase (augmentation de capital) of approximately 4.4 million euros through the issuance of new ordinary shares to a limited number of institutional investors. Key phrases include 'augmentation de capital', 'souscrite par un nombre limité d'investisseurs', 'émission au profit d'un nombre limité d'investisseurs institutionnels européens', and details about the issue price and use of proceeds. This clearly falls under the category of financing activities or capital structure changes. Therefore, the appropriate filing type code is 'CAP' (Capital/Financing Update). The document length is substantial (11,105 chars), indicating it is the primary announcement, not just a brief RPA.
2016-07-12 French
Mauna Kea Technologies Reports Second Quarter 2016 Sales
Earnings Release Classification · 100% confidence The document is titled "Mauna Kea Technologies Reports Second Quarter 2016 Sales" and contains key financial highlights (Revenue, cash burn rate) and detailed tables showing revenue results for Q2 2016 and 1H 2016. This structure, focusing on period-specific financial performance announcements, aligns perfectly with the definition of an Earnings Release (ER). Although it mentions a conference call, the primary content is the release of the results themselves, not just the announcement of the release (which would be RPA). It is not a comprehensive annual report (10-K) or a full interim report (IR), but rather the initial summary announcement of quarterly results. Q2 2016
2016-07-12 English
MAUNA KEA TECHNOLOGIES ANNONCE SON CHIFFRE D’AFFAIRES DU DEUXIÈME TRIMESTRE 2016
Earnings Release Classification · 100% confidence The document is titled "MAUNA KEA TECHNOLOGIES ANNONCE SON CHIFFRE D’AFFAIRES DU DEUXIÈME TRIMESTRE 2016" (Mauna Kea Technologies Announces its Second Quarter 2016 Revenue) and presents detailed financial figures for Q2 2016 and H1 2016, including revenue breakdowns by category, geography, and activity. This content structure is characteristic of an initial announcement of periodic financial results, focusing on key highlights and metrics rather than the comprehensive, audited statements found in a full Annual Report (10-K) or a detailed Interim Report (IR). The document explicitly mentions holding a conference call to present the results, which is typical for an Earnings Release (ER). It is not a transcript (CT), a full report (IR/10-K), or just a publication announcement (RPA). Q2 2016
2016-07-12 French
Mauna Kea Technologies: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont
Capital/Financing Update Classification · 99% confidence The document is a short announcement titled "Half-Yearly Report on the Liquidity Contract with Gilbert Dupont." It details the status of shares and cash held in a liquidity account as of June 30, 2016, comparing it to the previous report date (December 31, 2015). This content relates to the management of the company's own shares or capital structure, specifically concerning a liquidity agreement, which often involves share buybacks or stabilization activities. The closest fitting category is 'Transaction in Own Shares' (POS), as liquidity contracts are typically used for share repurchase programs or market stabilization. It is too specific for a general 'Capital/Financing Update' (CAP) and does not fit the criteria for an 'Interim Report' (IR) which would contain comprehensive financial statements. Given the focus on the share balance within a liquidity contract, POS is the most appropriate classification.
2016-07-06 English
Mauna Kea Technologies : Bilan semestriel du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont
Share Issue/Capital Change Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont" (Semi-annual balance sheet of the liquidity contract with Gilbert Dupont Stock Brokerage). It reports the status of a liquidity contract (likely a market-making or share buyback agreement) as of June 30, 2016, comparing it to the previous balance on December 31, 2015. This type of announcement, detailing the status of share transactions or financing arrangements (specifically related to liquidity provision), fits best under Capital/Financing Update (CAP) or Transaction in Own Shares (POS). Since it is a periodic report on the status of a liquidity contract involving shares and cash, it is most closely related to the company managing its capital structure or executing share transactions. Given the options, 'Transaction in Own Shares' (POS) covers share repurchase/issuance activities, which liquidity contracts often facilitate or report on. However, 'Capital/Financing Update' (CAP) is broader and often encompasses these activities. Since the text explicitly details the number of shares held under the contract and the cash balance, it is a direct report on a financing/capital management tool. Given the specific nature of reporting on a liquidity contract balance, POS is a strong candidate, but CAP covers financing activities generally. Let's re-evaluate the definitions. POS is for 'company buying back or selling its own shares'. A liquidity contract is a mechanism to support share price, often involving the broker buying/selling on the market. This is a report *about* that mechanism. CAP is for 'Updates on company fundraising, financing activities, or capital structure changes'. A liquidity contract is a financing activity. Given the context of reporting on the status of a formal agreement involving shares and cash, CAP seems slightly more appropriate than POS, which usually implies a direct declaration of a buyback program commencement/completion. However, if we consider the nature of the activity being reported (managing share availability/price), POS is also highly relevant. Since this is a periodic report on the execution of a specific share-related agreement, and not a general financing announcement, I will lean towards the most specific category related to share movement/management, which is POS, as liquidity contracts often involve the broker transacting shares. If POS is too narrow, CAP is the next best fit. Given the focus on the share count and cash balance related to the contract, POS is the most precise fit for reporting on the execution of share transactions via a third party.
2016-07-06 French
Mauna Kea Technologies: New Cellvizio Order Placed by UGAP for Rouen University Hospital
Regulatory Filings Classification · 99% confidence The document is a press release announcing a new order for the company's product (Cellvizio) from a French hospital purchasing group (UGAP). It contains company updates, product information, and standard disclaimers typical of a corporate news release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). Since it is a general corporate announcement disseminated via PR Newswire, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), the most appropriate general category for a non-standard, non-financial-specific corporate disclosure is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory announcements or press releases that don't fit elsewhere.
2016-06-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.